Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma
- (no title)
- (no title)
- (no title)
- FDA OKs multiple myeloma combo for all newly diagnosed patients
- Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review
- FDA fast tracks oral chemotherapy formulation for APL
- (no title)
- (no title)
- (no title)